Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Neumora Therapeutics, Inc. ( (NMRA) ) has shared an update.
On May 14, 2025, Neumora Therapeutics, Inc. received a notice from Nasdaq indicating non-compliance with the $1.00 minimum bid price requirement for its stock listing. The company has until November 10, 2025, to regain compliance, potentially through a reverse stock split, which will be voted on by stockholders on May 28, 2025. Failure to comply could lead to delisting, although the company may appeal or seek additional time.
The most recent analyst rating on (NMRA) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Neumora Therapeutics, Inc. stock, see the NMRA Stock Forecast page.
Spark’s Take on NMRA Stock
According to Spark, TipRanks’ AI Analyst, NMRA is a Underperform.
Neumora Therapeutics, Inc. is significantly challenged by its financial position, with ongoing losses and no revenue. Technical analysis indicates bearish momentum, and valuation is difficult in the absence of earnings. While promising pipeline advancements and a strong cash position offer some optimism, the overall outlook is hindered by recent clinical setbacks and financial instability.
To see Spark’s full report on NMRA stock, click here.
More about Neumora Therapeutics, Inc.
Average Trading Volume: 1,155,485
Technical Sentiment Signal: Sell
Current Market Cap: $99.49M
See more insights into NMRA stock on TipRanks’ Stock Analysis page.